UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-43048

 

NERVGEN PHARMA CORP.

(Exact name of Registrant as specified in its charter)

 

N/A
(Translation of Registrant’s name)

 

1200 Brickell Avenue, Suite 1950 #IP
Miami, Florida 33131
Telephone: (778) 731-1711

(Address and telephone number of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F¨                Form 40-F x

 

 

 

 

 

 

EXPLANATORY NOTE

 

Chief Medical Officer Appointment

 

On November 18, 2026, NervGen Pharma Corp. (the “Registrant” or “Company”) announced the appointment of Dr. Sam Jackson as Chief Medical Officer, effective December 7, 2026 (the “Effective Date”). Dr. Jackson will report directly to the Chief Executive Officer. A copy of the press release announcing Dr. Jackson’s appointment is filed hereto as Exhibit 99.1.

 

Dr. Jackson, age 60, brings more than 20 years of industry experience leading clinical development for novel neurologic, immunologic and ophthalmic programs. Dr. Jackson previously served as the Chief Medical Officer of Aditum Bio, a biotechnology investment and venture capital firm, where he managed the neuroscience portfolio from August 2025 to December 2026. Prior to that, Dr. Jackson held senior clinical roles at clinical stage and public biotechnology companies. He was Chief Medical Officer of Neuron23 Inc., from April 2022 to May 2025, and Chief Medical Officer (interim) / Senior Vice President Clinical Development at Alector, Inc. (Nasdaq: ALEC), from April 2020 to April 2022. Dr. Jackson is a board-certified physician and received his MD from the University of Pennsylvania, an MBA from The Wharton School at the University of Pennsylvania and a BA from Stanford University.

 

Pursuant to an offer letter (the “Offer Letter”), signed November 16, 2026, between NervGen US Inc., a wholly owned subsidiary of the Company (“NervGen U.S.”), and Dr. Jackson governing the terms of his employment, Dr. Jackson will be paid an annualized base salary of $525,000. Beginning with fiscal year 2027, he will be eligible to receive an annual incentive bonus with a target of 40% of his base salary, based on the achievement of Company and individual performance objectives established by the Compensation Committee of the Board (the “Committee”). Pursuant to a separate sign-on bonus agreement (the “Bonus Agreement”), Dr. Jackson will also receive a one-time sign-on bonus of $208,000 in lieu of any 2026 annual bonus. The sign-on bonus is payable in two installments: $100,000 following the Effective Date and $108,000 on or after March 31, 2027, subject to Dr. Jackson's continued employment through such date, and subject to certain adjustments set forth in the Bonus Agreement.

 

The Company will grant Dr. Jackson stock options (the “Options”) to purchase up to 1,156,135 common shares of the Company, effective on the Effective Date, with an exercise price per share equal to the closing price of the Company's common shares on the Nasdaq Capital Market on the Effective Date. The Options will be exercisable for a period of ten years and are scheduled to vest over a four-year period, with 25.0% vesting on the first anniversary of the Effective Date and the remaining 75.0% vesting in thirty-six substantially equal monthly installments thereafter, subject to Dr. Jackson’s continued service through each applicable vesting date. On the Effective Date, and subject to the terms of the Offer Letter, the Company will also grant Dr. Jackson 50,000 restricted share units, which vest in full only if at least 150 participants have been randomized and enrolled in the RESTORE study on or before August 1, 2027 and Dr. Jackson remains in service through such milestone.

 

In addition, the Offer Letter provides that Dr. Jackson will be eligible to participate in the employee benefit plans made available to the Company’s senior executives. It also provides that he will enter into the Company’s standard form of indemnity agreement and be covered under its directors’ and officers’ liability insurance.

 

Pursuant to the Offer Letter, if Dr. Jackson’s employment is terminated by NervGen U.S. without cause or by Dr. Jackson for good reason outside a change in control period, NervGen U.S. is obligated to (1) continue to pay Dr. Jackson’s base salary for nine months, (2) pay any earned but unpaid annual bonus for the prior fiscal year and (3) pay the employer portion of his health coverage premiums under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), for up to nine months. If such a termination occurs within three months before or twelve months after a change in control, Dr. Jackson will be entitled to (1) a lump sum payment equal to twelve months of base salary plus 100% of his target bonus, (2) any earned but unpaid prior-year bonus, (3) COBRA premiums for up to twelve months and (4) the vesting of all outstanding and unvested time-based equity awards. Severance benefits are conditioned on Dr. Jackson’s execution of a general release of claims. All incentive-based compensation is subject to the Company's Compensation Recovery Policy.

 

The foregoing descriptions of the Offer Letter and Bonus Agreement do not purport to be complete and are subject to and qualified in their entirety by reference to the full text of the Offer Letter and Bonus Agreement. A copy of the Offer Letter and Bonus Agreement are filed as Exhibit 10.1 to this Report on Form 6-K.

 

 

 

INCORPORATION BY REFERENCE

 

This Report on Form 6-K, including Exhibits 10.1 and 99.1, is incorporated by reference into the Registrant’s Registration Statement on Form F-10 (File No. 333-296217) and the Registrant’s Registration Statements on Form S-8 (File Nos. 333-292927 and 333-295632), to be a part thereof from the date on which this Report on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

Exhibit    
     
10.1   Offer Letter and Sign-On Bonus Agreement by and between NervGen U.S. and Sam Jackson, signed November 16, 2026.
99.1   Press Release, dated November 18, 2026.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  NERVGEN PHARMA CORP.
     
Date: November 18, 2026 By: /s/ Adam Rogers  
    Name: Adam Rogers
    Title: Chief Executive Officer

 

 

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EXHIBIT 10.1

EXHIBIT 99.1